RWM
BIO icon

Rialto Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rialto Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06K Buy
7
+6
+600% +$1.7K ﹤0.01% 1112
2026
Q1 		$279 Sell
1
-1
-50% -$288 ﹤0.01% 1551
2025
Q4 		$606 Hold
2
– – ﹤0.01% 1180
2025
Q3 		$561 Buy
+2
New +$544 ﹤0.01% 1165

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rialto Wealth Management's BIO Position: Q2 2026 in Review

Rialto Wealth Management increased its Bio-Rad Laboratories Class A (BIO) stake by 600% in Q2 2026, buying an estimated $1.7K and bringing the position to 7 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

Rialto Wealth Management first reported a position in BIO in Q3 2025 and has held it in 4 quarters since. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Rialto Wealth Management held 7 shares of Bio-Rad Laboratories Class A worth $2.06K as of Q2 2026.
  • Rialto Wealth Management bought 6 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.7K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1112 holding.
  • Rialto Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 4 quarters since.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.